---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Mechanism of action"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Mechanism of action. Topics: Protein kinase C signaling downstream of mutant GNAQ and GNA11; Darovasertib: oral, selective inhibitor of classical and novel PKC isoforms; Second-generation PKC inhibitor with activity restricted to GNAQ- or GNA11-mutant uveal melanoma cell lines; Rationale for combined PKC and MET inhibition: hepatocyte growth factor in the liver and MET overexpression; 1 further topic. 5 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Protein kinase C signaling downstream of mutant GNAQ and GNA11

> “A key downstream player of the constitutively active G-protein alpha subunits (GNAQ or GNA11) is the phospholipase C/protein kinase C (PKC) signalling pathway.”
> “PKC signalling is a key node in the maintenance of cellular homoeostasis; in UM cells, it results in phosphorylation and increased transcript expression of RasGrp3, a guanine nucleotide exchange factor that transduces signalling from GNAQ/GNA11 to the MAPK signalling pathway through PKC delta”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

> “One of the key downstream targets of the constitutively active Gq alpha subunits is the protein kinase C (PKC) signaling pathway.”

Source: [Visser et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38198520/)

> “We are developing darovasertib for uveal melanoma (UM), a rare, aggressive form of ocular cancer in which approximately 95% of patients harbor activating mutations in GNAQ/11 GTPase proteins that drive downstream PKC signaling and tumor cell growth.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.1.2.6.1-2"></a>

### Darovasertib: oral, selective inhibitor of classical and novel PKC isoforms

> “Darovasertib (previously known as IDE196 and LXS196) is an oral, potent, selective inhibitor of the classical (α, β) and novel (δ, ε, η, θ) PKC isoforms”
> “Consistent with its selective targeting of PKC, darovasertib potently inhibits the growth of UM cell lines containing mutant GNAQ or GNA11”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

> “Our most advanced product candidate, darovasertib, is an oral, potent and selective PKC inhibitor currently in multiple clinical trials in both the metastatic and pre-metastatic settings of UM.”

Source: [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

> “Darovasertib is an oral, selective inhibitor of PKC, the key oncogenic driver in >95% of patients”

Source: [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf)

<a id="topic-2.1.2.6.1-3"></a>

### Second-generation PKC inhibitor with activity restricted to GNAQ- or GNA11-mutant uveal melanoma cell lines

> “LXS196 is a potent, second-generation, oral PKC inhibitor designed with improved pharmaceutical properties compared with AEB071.”
> “LXS196 has a highly selective kinase profile affording increased tolerability in preclinical studies, with cellular activity restricted to UM cell lines containing mutant GNAQ or GNA11 and no activity observed in skin-derived melanoma cell lines driven by mutant B-Raf or N-Ras”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-2.1.2.6.1-4"></a>

### Rationale for combined PKC and MET inhibition: hepatocyte growth factor in the liver and MET overexpression

> “MET overexpression and resultant pathway activation has been associated with UM tumor metastasis and correlates with poor disease prognosis.”
> “Of relevance, overexpression of MET is observed in approximately 60%-86% of cases of mUM”
> “In preclinical studies, combined inhibition of PKC and c-MET resulted in greater antitumor activity than inhibition of either pathway alone”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

> “The liver microenvironment has high levels of HGF, and high MET receptor expression in UM is associated with metastatic progression.”
> “In order to identify combination partners for IDE196, we hypothesized that the rich growth factor microenvironment in the liver may prevent MUM tumor cells from responding to IDE196 and that a combination of IDE196 with a MET inhibitor may synergistically inhibit tumor cell proliferation.”

Source: [Wagle et al. (2021)](https://aacrjournals.org/cancerres/article/81/13_Supplement/1343/667196/Abstract-1343-Preclinical-evaluation-of-a-PKC-and)

> “In the adjuvant setting and in metastatic UM (mUM), darovasertib is combined with crizotinib, an oral inhibitor of the cMET pathway, which is believed to play a central role in metastatic spread”

Source: [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf)

<a id="topic-2.1.2.6.1-5"></a>

### Crizotinib label: inhibition of ALK, c-Met, ROS1, and RON receptor tyrosine kinases

> “Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 (c-ros), and Recepteur d’Origine Nantais (RON).”
> “Crizotinib demonstrated concentration-dependent inhibition of ALK, ROS1, and c-Met phosphorylation in cell-based assays using tumor cell lines and demonstrated antitumor activity in mice bearing tumor xenografts that expressed echinoderm microtubule-associated protein-like 4 (EML4)- or nucleophosmin (NPM)-ALK fusion proteins or c-Met.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
